一例高血壓性心臟病的循證研究(更新版)
【正文】 2mg, 5mg, , 1mg, 3次2次1次1次1次2次1次1次50mg, 1020 mg, 40mg, 2040mg 816mg 20mg 10mg 4mg, 3次2次1次1次1次2次1次1次ARB 坎地沙坦氯沙坦纈沙坦48mg, 2550mg, 2040mg, 1次1次2次32mg, 50100mg, 160mg, 1次1次2次醛固酮拮抗劑螺內(nèi)酯依普利酮, 25mg, 1次1次25mg, 50mg, 12次1次β受體阻滯劑 比索洛爾卡維地洛緩釋琥珀酸美托洛爾 , , , 1次2次1次10mg, 25mg, 50mg, (體重超過85公斤)200mg, 1次2次2次1次洋地黃：已經(jīng)應(yīng)用利尿劑、ACEI（或ARB）和β受體阻滯劑但心衰癥狀不能緩解的患者可考慮加用洋地黃類藥物。若心衰癥狀較重可加用醛固酮受體拮抗劑。11.3. Khan, ., et al., The 2008 Canadian Hypertension Education Program remendations for the management of hypertension: part 2 therapy. Can J Cardiol, 2008. 24(6): p. 46575.4. Mancia, G., et al., 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2007. 28(12): p. 1462536.5. Hunt, ., et al., ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005. 112(12): p. e154235.6. Bangalore, S., et al., Betablockers for primary prevention of heart failure in patients with hypertension insights from a metaanalysis. J Am Coll Cardiol, 2008. 52(13): p. 106272. 內(nèi)容總結(jié)
（1）一例高血壓性心臟病的循證研究
臨床醫(yī)學(xué)（八）044212 葉江川
一、臨床資料
女性，58歲
教學(xué)教案相關(guān)推薦
鄂ICP備17016276號-1